Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
All news
Biotechnology
UCB has announced the initiation of a Phase III clinical trial evaluating the efficacy and safety of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SoC) medication for lupus. 12 March 2020
Biotechnology
Oslo, Norway-based Zelluna Immunotherapy is partnering with the Swedish Karolinska Institutet (KI) to develop next generation novel immuno-oncology products for the treatment of solid cancers. 12 March 2020
Biotechnology
Shares of Israeli biotech firm Protalix BioTherapeutics, which are also traded in New York, were up 10.6% at $2.61 in morning activity, after the company said it has successfully secured securities purchase agreements to raise $43.7 million through a private equity investment (PIPE) in the company. 12 March 2020
Biotechnology
Canada-based ImmunoPrecise Antibodies, following its announcement to develop innovative treatments against the new coronavirus, SARS-CoV-2, unveils its unique approach utilizing PolyTope mAb Therapy, enabled by IPA's diverse discovery platforms and artificial intelligence capabilities with their partner, EVQLV Inc, in the development of a universal COVID-19 therapy. 12 March 2020
Biotechnology
Phio Pharmaceuticals Corp, a US biotech developing immuno-oncology (I-O) drugs based on its self-delivering RNAi (INTASYL) therapeutic platform, is to collaborate with MediGene AG to advance compounds in adoptive cell therapy to enhance immune cell function. 12 March 2020
Biotechnology
Once hotly-tipped biotech Intarcia Therapeutics has been dealt a bodyblow from the US regulator, with a second rejection for its drug-device combination ITCA-650. 12 March 2020
Biotechnology
Disappointing high-level results from the Phase III GY004 trial, led by NRG Oncology and sponsored by the US National Cancer Institute (NCI), that examined primarily the efficacy and safety of the potential new medicine Recentin (cediranib) added to Lynparza (olaparib) versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer have been released . 12 March 2020
Biotechnology
The UK National Institute for Health and Care Excellence (NICE) has recommended Ajovy (fremanezumab) for preventing chronic migraine. 12 March 2020
Biotechnology
Bristol Myers Squibbhas added a new indication to the US label for Opdivo (nivolumab) plus Yervoy (ipilimumab), to treat hepatocellular carcinoma (HCC). 11 March 2020
Biotechnology
Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, today announced that Lisa Johnson-Pratt has joined the company as senior vice president of new product strategy. 11 March 2020
Biotechnology
Horama, the ophthalmic gene therapy company, has named Rodolphe Clerval as its chief business officer. 11 March 2020
Biotechnology
French ophthalmology focussed biotech firm Nicox has amended its March 2019 license agreement with China’s Ocumension Therapeutics granting the latter exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis in the Chinese market. 11 March 2020
Biotechnology
Shares of UK biotech Tiziana Life Sciences went ballistic this morning, after the company revealed that it is expediting development of TZLS-501, a novel, fully-human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (MAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). 11 March 2020
Biotechnology
The US Food and Drug Administration has granted Breakthrough Therapy designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. 11 March 2020
Biotechnology
UK company George Health has announced £27 million ($35 million) in new financing to accelerate the commercialization of drugs and technologies for some of the world’s most destructive diseases. 10 March 2020
Biotechnology
The US Food and Drug Administration on Monday approved Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). 10 March 2020
Biotechnology
Investor LSP has closed the largest ever European life sciences fund. 10 March 2020
Biotechnology
Stock in Stockholm-based Cantargia has been lifted by news the firm has bought an important patent portfolio from Cellerant Therapeutics. 10 March 2020
Biotechnology
Basel-based Myovant Sciences, a company focused on women's health and prostate cancer that is now majority-owned by Japanese drug major Sumitomo Dainippon Pharma, is closing in on a major market with its lead product. 10 March 2020
Biotechnology
US biotech CEL-SCI Corporation has announced that it is developing an immunotherapy with the potential to treat the COVID-19 coronavirus. 10 March 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze